PMID: 2508092Oct 1, 1989Paper

Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator

Proceedings of the National Academy of Sciences of the United States of America
D J Fitzgerald, G A FitzGerald

Abstract

Reocclusion of the coronary artery occurs after thrombolytic therapy of acute myocardial infarction despite routine use of the anticoagulant heparin. However, heparin is inhibited by platelet activation, which is greatly enhanced in this setting. Consequently, it is unclear whether thrombin induces acute reocclusion. To address this possibility, we examined the effect of argatroban [MCI9038, (2R,4R)-4-methyl-1-[N alpha-(3-methyl-1,2,3,4-tetrahydro-8- quinolinesulfonyl)-L-arginyl]-2-piperidinecarboxylic acid], a specific thrombin inhibitor, on the response to tissue-type plasminogen activator in a closed-chest canine model of coronary thrombosis. MCI9038 prolonged the thrombin time and shortened the time to reperfusion (28 +/- 2 min vs. 59 +/- 7 min in controls; mean +/- SEM, n = 5, P less than 0.01). At the highest dose, 2.5 mg/kg per hr, complete reocclusion was prevented in four of the five experimental animals, whereas reocclusion occurred in all five controls. However, reperfusion was complicated by cycles of decrease flow, which were abolished by the thromboxane A2 antagonist, GR32191. GR32191 at 1 mg/kg combined with MCI9038 at 0.5 mg/kg per hr prevented reocclusion, whereas, at these doses, either drug alone was without ...Continue Reading

References

Sep 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·J P MiletichP W Majerus
Feb 1, 1989·Thrombosis Research·S KobayashiT Tsunematsu
Feb 1, 1986·The Journal of Clinical Investigation·D J FitzgeraldG A FitzGerald
Oct 6, 1988·The New England Journal of Medicine·J Loscalzo, E Braunwald
Nov 1, 1988·The Journal of Clinical Investigation·D J FitzgeraldG A FitzGerald
Jun 9, 1988·The New England Journal of Medicine·V J Marder, S Sherry
Jul 1, 1986·Seminars in Thrombosis and Hemostasis·J W Fenton, D H Bing
Sep 1, 1987·Journal of the American College of Cardiology·P R EisenbergA S Jaffe
Sep 15, 1987·Thrombosis Research·F Catella, G A FitzGerald
Feb 1, 1987·The American Journal of Cardiology·K KaplanM Salinger
May 1, 1983·The Journal of Clinical Investigation·J M Teitel, R D Rosenberg

❮ Previous
Next ❯

Citations

May 1, 1996·Journal of Cellular Biochemistry·R Bar-ShavitI Vlodavsky
Sep 1, 1991·Medicinal Research Reviews·S E Hall
Nov 15, 1991·Journal of the American College of Cardiology·S FujiiB E Sobel
Jul 1, 1992·Journal of the American College of Cardiology·F A NicoliniC Mattsson
Apr 1, 1993·Journal of the American College of Cardiology·J T Willerson, W Casscells
Jul 1, 1993·Journal of the American College of Cardiology·N A PragerD R Abendschein
Nov 1, 1995·Journal of the American College of Cardiology·T TomaruY Uchida
Mar 1, 1991·Trends in Cardiovascular Medicine·F A Fitzpatrick
Sep 1, 1991·Trends in Cardiovascular Medicine·L BadimonV Fuster
Jan 1, 1991·Trends in Cardiovascular Medicine·D J Fitzgerald, G A Fitzgerald
Mar 1, 1994·Trends in Cardiovascular Medicine·S R Coughlin
Oct 29, 2000·Thrombosis Research·R PakalaC R Benedict
Apr 9, 1998·Prostaglandins·J RokachG A FitzGerald
Jan 11, 2001·Journal of Pharmacological and Toxicological Methods·R J LeadleyA Gagnon
Jan 30, 1992·The New England Journal of Medicine·V FusterJ H Chesebro
Jan 25, 2008·The New England Journal of Medicine·Roger Kapoor, John R Kapoor
Nov 29, 2012·Journal of Cardiovascular Pharmacology·Jullia Y LeeBenedict R Lucchesi
Feb 22, 2012·Arteriosclerosis, Thrombosis, and Vascular Biology·Jose A DiazThomas W Wakefield
Jan 5, 2013·Circulation Research·Desmond J Fitzgerald, Garret A Fitzgerald
Nov 1, 1991·The Journal of Clinical Investigation·D J FitzgeraldG A FitzGerald
Feb 1, 1992·The Journal of Clinical Investigation·S R CoughlinV I Wheaton
Oct 1, 1992·The Journal of Clinical Investigation·N A NelkenS R Coughlin
Nov 1, 1992·Clinical Cardiology·P Jain, S C Vlay
Jul 5, 2005·Expert Opinion on Investigational Drugs·W JeskeJ Fareed
Apr 18, 1994·Annals of the New York Academy of Sciences·D Fitzgerald

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.